EHA 2015 | ELOQUENT-2 trial: Elotuzumab for relapsed or refractory multiple myeloma

Jesús San Miguel

At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of the randomized, open-label phase 3 trial of lenalidomide plus dexamethasone with or without elotuzumab, a monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), for the treatment of patients with relapsed or refractory multiple myeloma.

Share this video